Mochida Pharmaceutical
4534.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥117.0bn | ¥105.2bn | ¥102.9bn | ¥103.3bn | ¥110.2bn | ¥103.0bn |
| Operating income | ¥10.1bn | ¥8.1bn | ¥5.8bn | ¥8.5bn | ¥14.4bn | ¥12.0bn |
| Ordinary income | ¥11.2bn | ¥8.1bn | ¥6.0bn | ¥9.1bn | ¥14.8bn | ¥12.3bn |
| Net income (owners) | ¥7.9bn | ¥5.7bn | ¥4.5bn | ¥6.6bn | ¥10.6bn | ¥8.6bn |
| Total assets | ¥182.7bn | ¥160.1bn | ¥158.8bn | ¥158.8bn | ¥163.1bn | ¥161.8bn |
| Net assets / equity | ¥140.3bn | ¥130.7bn | ¥128.0bn | ¥126.8bn | ¥128.6bn | ¥127.0bn |
| Operating cash flow | −¥7.3bn | ¥9.4bn | −¥7.5bn | ¥7.3bn | ¥7.5bn | ¥9.2bn |
| EPS (basic) | ¥222.96 | ¥160.36 | ¥126.8 | ¥178.93 | ¥277.39 | ¥222.29 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 197 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 67 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 197 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 67 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 197 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 45 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 69 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 43 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 197 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 45 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 69 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 43 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 197 figures · EDINET |
21 more reports are still being processed.